Search research articles
Contact Us
Filters
Showing results (191-200 of 293) with videos related to
Page
of 30
Sort By:
BMC Medical Genomics
|
November 5, 2020
Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape
Tito Fojo, Lyn Huff, Thomas Litman, et al.
Current Problems in Cancer
|
June 10, 2022
Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities
Stacyann Bailey, Qian Wang, Chung Yin Kong, et al.
Molecular Cancer Therapeutics
|
December 20, 2007
New inhibitors of ABCG2 identified by high-throughput screening
Curtis J Henrich, Robert W Robey, Heidi R Bokesch, et al.
Biochemistry
|
July 21, 2004
Mutational analysis of ABCG2: role of the GXXXG motif
Orsolya Polgar, Robert W Robey, Kuniaki Morisaki, et al.
Cancer Research
|
September 17, 2005
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates
Assaf Shafran, Ilan Ifergan, Eran Bram, et al.
Expert Review of Anticancer Therapy
|
July 22, 2010
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant, Fahd Rahman, Richard Piekarz, et al.
Experimental Cell Research
|
December 24, 2018
Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models
Andrew J McDonald, Katherine M Curt, Ruchi P Patel, et al.
Cancer Research
|
July 5, 2005
Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment
Dezheng Dong, Bryce Ko, Peter Baumeister, et al.
Blood
|
May 3, 2002
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia
Dorina M van der Kolk, Edo Vellenga, George L Scheffer, et al.
Journal of Biomolecular Screening
|
February 24, 2006
A high-throughput cell-based assay for inhibitors of ABCG2 activity
Curtis J Henrich, Heidi R Bokesch, Michael Dean, et al.
Page
of 30
Search research articles
Search
Showing results (191-200 of 293) with videos related to
Sort By:
Page
of 30
BMC Medical Genomics
|
November 5, 2020
Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape
Tito Fojo, Lyn Huff, Thomas Litman, et al.
Current Problems in Cancer
|
June 10, 2022
Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities
Stacyann Bailey, Qian Wang, Chung Yin Kong, et al.
Molecular Cancer Therapeutics
|
December 20, 2007
New inhibitors of ABCG2 identified by high-throughput screening
Curtis J Henrich, Robert W Robey, Heidi R Bokesch, et al.
Biochemistry
|
July 21, 2004
Mutational analysis of ABCG2: role of the GXXXG motif
Orsolya Polgar, Robert W Robey, Kuniaki Morisaki, et al.
Cancer Research
|
September 17, 2005
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates
Assaf Shafran, Ilan Ifergan, Eran Bram, et al.
Expert Review of Anticancer Therapy
|
July 22, 2010
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant, Fahd Rahman, Richard Piekarz, et al.
Experimental Cell Research
|
December 24, 2018
Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models
Andrew J McDonald, Katherine M Curt, Ruchi P Patel, et al.
Cancer Research
|
July 5, 2005
Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment
Dezheng Dong, Bryce Ko, Peter Baumeister, et al.
Blood
|
May 3, 2002
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia
Dorina M van der Kolk, Edo Vellenga, George L Scheffer, et al.
Journal of Biomolecular Screening
|
February 24, 2006
A high-throughput cell-based assay for inhibitors of ABCG2 activity
Curtis J Henrich, Heidi R Bokesch, Michael Dean, et al.
Page
of 30